top of page

2026 POSTER ABSTRACTS

(Download abstract list as PDF)
Abstract #
Abstract Title
POSTER SESSION 1: October 28 4:30-6:30 PM ET
The Gupta Family Endowed Prize for Innovation in ALS Care
Drs. Ayeez and Shelena Lalji & Family Student Scholar Award for Repair and Regenerative Mechanisms in ALS
1
An Astrocyte Signature That Replicated Across Three ALS Cohorts and Still Was Not Real: The Case for Out-of-Sample Validation
2
NU-9 Treatment in Three Different ALS Models Validate Mitochondrial Integrity Restoration, Introducing Circulating cf-mtDNA as a Potential Target Engagement Biomarker
3
Exosome Proteomics of Serum from Patients with SOD1D90A Mutation and at Different Stages of their Disease Reveal Changes in Disease Mechanisms, and potential biomarkers
4
Toward trustworthy remote speech biomarkers in ALS: modeling recording quality as a multidimensional measurement property
5
Objective muscle strength (NOVA-IMS): a prespecifiable, outcome-independent stratifier of progression rate for ALS trials with ALSFRS-R as the primary outcome
6
Baseline Biomarker Predictors of Neurofilament Light Chain Response to Oral Fasudil in ALS: An Exploratory Analysis from the REAL Phase 2 Study
7
Mitigating Clinical Heterogeneity in ALS Trials: The Biological Rationale and Statistical Impact of 3-Tiered Neurofilament Light (NfL) Stratification in the ALSTARS Trial
8
On-Treatment NfL Response Identifies a Two-Year Survival Difference in RESCUE-ALS and Replicates Across Two Independent CNM-Au8 Trials
9
Treatment Benefit of CNM-Au8 in the HEALEY ALS Platform Trial Is Concentrated in Participants with On-Treatment NfL Decline or Stabilization: Concordance and Randomization-Anchored Causal Analyses
10
Metabolomics and Lipidomics Signatures and Machine Learning Algorithms to Differentiate ALS and PLS
11
ALSmiR: A curated community resource for ALS MicroRNA biomarker discovery
12
ERACE (Emory Rapid Access Clinical Evaluation) 10-protein model predicts ALS from plasma with high accuracy
13
Serum Neurofilament Light Chain characterization using data collected from the HEALEY ALS Platform Trial
14
Longitudinal Neurofilament Light Chain Trajectory Is Associated with Survival in ALS: Prespecified Analyses Across Two Independent Cohorts
15
Retinal OCT and OCTA Biomarker Readiness in Amyotrophic Lateral Sclerosis: A Systematic Review of Longitudinal Evidence, Disease-Stage Effects, and Methodological Quality
17
Preliminary Support for a Divergence Between Central and Peripheral Motor Excitability in ALS
18
Network of Excellence for Amyotrophic Lateral Sclerosis (NEALS) Biorepository
19
Utilization of Wrist-Worn Actigraphy to Evaluate Patient-Reported Fatigue and Sleep in a Pilot ALS Cohort
21
Free-Living Ambulation Tracking in ALS Using Wearable Sensors
22
Remotely collected wearable digital data can detect development of comorbid disease in ALS.
23
Plasma tau phosphorylated at T181 is elevated in amyotrophic lateral sclerosis
24
Evaluation of Oculomotor Function for Monitoring Disease Progression in Amyotrophic Lateral Sclerosis
25
Designing ALS Trials using Serum Neurofilament Light Chain as an efficacy outcome: Operational Evidence from the HEALEY ALS Platform Trial
26
Plasma and CSF Biomarkers to Predict ALS Disease Progression
27
Quantitative ALS: Preliminary Validation of a Novel ALS Outcome Measure
28
Vimentin (VIM) Cryptic Exons as a Blood Biomarker of ALS
29
Characterizing microbial markers predictive for ALS onset and progression
30
The Accelerating Medicines Partnership® in Amyotrophic Lateral Sclerosis (AMP® ALS) Program: Building a Collaborative Framework for Biomarker and Therapeutic Advancement
31
Evaluation of consistency of Olink HT proteomics in ALS biofluids
32
Digital Split-Hand Index: Pilot Study of A Smartphone-Based Biomarker for Detecting Selective Motor Vulnerability in ALS
33
iBrain™ as a Remote Monitor of EEG and Sleep Activity in Amyotrophic Lateral Sclerosis
34
The Effect of Edaravone on CSHE in ALS and the Utility of SICI as a Pharmacodynamic Biomarker
35
From etiology to therapeutics of Lou Gehrig’s disease
36
DPTX3230 Restores TDP-43 Nuclear Function Across Translational Models of ALS
37
IKZF1 Links Peripheral Myeloid and Microglial Dysregulation in ALS: Concordant, Out-of-Sample Validation Across Six Single-Cell Cohorts
38
Presence of Somatic Mutations in sporadic ALS
39
Prevention of Unc13a cryptic splicing is sufficient to preserve memory
40
RNA processing dysregulation and fusion transcript formation in ALS
41
IPL344: DNA-damage-response-driven neuro-regeneration in ALS
42
Preclinical development of antisense oligonucleotide TRCN-1023 to restore UNC13A function in people living with Amyotrophic Lateral Sclerosis
43
Molecular Vulnerability of Upper Motor Neurons Despite Preserved Neuronal Composition in the ALS Motor Cortex
44
Epigenetic regulation of upper motor neuron vulnerability within the context of TDP-43 pathology
45
Proteomic Analyses Begin to Reveal Target Engagement and Efficacy of NU-9 in a Model of Misfolded SOD1 Toxicity
46
A High-Density Microelectrode Array Reveals That Corticospinal Motor Neurons With TDP-43 Pathology Are Prone To Hyperexcitation At Birth
48
RKER-065, an Activin/Myostatin Ligand Trap, Mitigated Disease Progression and Improved Muscle Function in an Amyotrophic Lateral Sclerosis Mouse Model
49
Treatment With a Stable GDNF Variant Improved Clinical Outcomes in a Mouse Model of Amyotrophic Lateral Sclerosis
50
RKER-065 preserved bone structure and function during disease progression in the SOD1-G93A mouse model of ALS
51
Shared targets and binding-site enrichment implicate RBFOX2 as a co-regulator of TDP-43-responsive splicing in human neurons
52
Bypassing the Blood-Brain Barrier: Systemic Delivery of SYT2-Targeted siSOD1 to Lower Motor Neurons Attenuates Motor Decline in SOD1-G93A Mice
53
The Development and Optimization of AAV-mediated Gene Medicine as Potential ALS Therapeutics
54
Injury-induced local axonal translation of importin-β1 supports motor axon regeneration and is disrupted by dipeptide repeat proteins in C9orf72 ALS
55
Prodromal Gene Expression Changes in the Spinal Cord of a Large Animal Model of Motor Neuron Degeneration
56
Preclinical characterization of prosetin, a novel, CNS-penetrant MAP4K inhibitor developed for the treatment of ALS
57
Impact of INS1202 AAV9-SOD1-shRNA Gene Therapy on Motor Neuron Survival and Hallmarks of Neurodegeneration in a Sporadic ALS Patient-Derived In Vitro Model
60
Performance of Quantitative Speech Metrics as Longitudinal Progression Markers in ALS
61
Baseline Enrichment to Increase Statistical Power of Quantitative Speech Metrics as Secondary Endpoints in ALS Clinical Trials
62
Caregiver-Supported Oral Hygiene Protocol in ALS: A Randomized Crossover Pilot Study
63
Spontaneous tonic chin dimpling associated with corticobulbar involvement in ALS
64
Speech-Language Pathology-Led Communication Planning for Gastrostomy in ALS/MND: Integration of Serious Illness Communication Principles and Anticipatory AAC Supports
65
Anticipating Feeding Tube Placement in ALS: Milestone Clustering and Baseline Predictors of Timing
66
A Proactive, Multisystem, Tiered Framework for Communication Management in ALS
67
Preliminary Evidence of a Short-Form Swallowing Quality of Life Measure in ALS
68
Effects of Combined Lung Volume Recruitment and Expiratory Strength Training on Pulmonary and Cough Function in People Living with ALS
69
Speech-Language Pathologists’ Knowledge and Clinical Confidence Following a Dysphagia Masterclass on MND/ALS Management
70
Texture Classification and Oral Processing of Commercially Available Protein Bars: Preliminary IDDSI Reference Data Relevant to Dysphagia and Nutritional Management
71
Differentiating Spinal- and Bulbar-Onset ALS: A Comparative Analysis of Remote Digital Speech Metrics and Spirometry
72
Psychological symptoms and swallowing difficulty in ALS: An exploratory pilot survey study
73
Associations of Bulbar Impairments with Social Connection in ALS: Preliminary Findings
74
Subclinical changes in speech metrics in individuals with spinal-onset ALS
75
Composite Speech Biomarkers for ALS: Reliability, Measurement Error, and Generalization from Natural History to Clinical Trial
76
Implementation of ALS Genetic Testing Guidelines: Uptake, Impact, and Opportunities at a Single ALS Center
77
Genetic Counseling and Testing Utilization in Individuals At-Risk for ALS/FTD Spectrum Disorders
78
Amyotrophic Lateral Sclerosis Genetic profile among cases reported in the CELA-PR Registry
79
Insights from sponsored genetic testing in patients with amyotrophic lateral sclerosis: A single-site retrospective study
80
Implementation of an ALS Prevention Continuum for Individuals at Genetic Risk of Amyotrophic Lateral Sclerosis
81
Examining the Clinical and Genetic Spectrum of TARDBP-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
82
Motor neuron disease associated with biallelic repeat expansions in RFC1
83
Assessing penetrance in genetic ALS: Implications for genetic counseling and predictive testing
84
Taskforce on Genetic Counselling and Testing in ALS/MND: Developing Global Consensus-Based Guidelines
85
PREVENT ALL ALS: Cohort description of a national ALS gene carrier study
86
Multimodal MRI to assess ALS progression over three to six months: Preliminary data from multicenter imaging study
87
Practice Parameters identified by Occupational Therapy Practitioners when working with persons with ALS: A Cross-Sectional Survey
88
Home-Based Neuromuscular Electrical Stimulation for Preservation of Function in Amyotrophic Lateral Sclerosis: Rationale and Study Design
89
The Nova-IMS: Concurrent Validity of Isometric Muscle Strength Testing Across Four Functional Domains and the ALSFRS-R Ceiling Effect in ALS
90
Evaluation of a Progressive Training Regimen to Extend ALS Patients' Functional Independence through Autonomous Wheelchair Control
91
Implementation and Analysis for Minimally Important Difference (MID) for the ALSFRS-R in the ASSESS ALL ALS study
92
The Rasch-Overall ALS Disability Scale (ROADS): Longitudinal Characteristics and Survival Predictions
93
Dynamic Weighting of External Factors Affecting Longitudinal ALSFRS-R Scores
94
A Harmonized Multisite Digital TDP-43 Pathology Resource Enables Automated Quantitative Analysis Across ALS and FTD
95
Performance of the Self-Reported ALS Functional Rating Scale-Revised in the ALL ALS Study
96
Towards restoring bimanual motor function for people with tetraplegia.
97
Association between dietary intake and blood glucose dynamics among C9orf72 ALS and asymptomatic gene-carriers
98
Correlation of Neurofilament Light-chain Levels and Body Composition with Survival in Amyotrophic Lateral Sclerosis
99
Comparison of Elective vs. Non-Elective Feeding Tube Placements Among Patients with ALS
100
Gastrointestinal symptoms pre and post feeding tube placement in people living with ALS
101
MIND Diet Adherence Is Associated with Reduced Circulating Inflammatory Biomarkers in ALS
102
Respiratory Care and Ventilation (RCV) Committee of the Network for Excellence in Amyotrophic Lateral Sclerosis (NEALS) Patient Care Status-Future Needs Assessment Surveys 2010-2024: Longitudinal Platform for Identifying GapsChallenges in USA ALS Care/Educational Opportunities to Deploy Best Practices
104
Correlation Between Subjective Respiratory Symptoms And Objective Respiratory Parameters In Patients With Amyotrophic Lateral Sclerosis: Experience From A Chilean Center
105
At-Home Telespirometry Identifies Baseline Erect Slow Vital Capacity (eSVC) at ≤80%-Predicted as a Pivotal Benchmark Separating Rapid From Less Rapid Decline in eSVC, Supine SVC and Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised Score in Observational Study (NCT05106569)
106
Differential Respiratory Correlations in Amyotrophic Lateral Sclerosis: The Effect of Site of Onset on Clinical Markers
107
Development of a Multidisciplinary Motor Neuron Disease Clinic in Chile: A Seven-Year Experience
109
A Prompt-Engineered Large Language Model Pipeline to Improve ALS Referral Triage Efficiency - A Pilot Study
110
Bridging the Gap: Electronic Questionnaires to Enhance ALS Patient Engagement and Research Interest
111
The Rapid Access ALS Clinic Model: A Step Towards Addressing ALS Diagnostic Delay
112
Evaluating Leadership-Driven Workflow Redesign to Improve Referral Coordination in Multidisciplinary ALS Clinics
113
Evaluating the VA ALS System of Care: A Literature Review
114
Emergencies in a Multidisciplinary ALS Clinic Cohort: Massachusetts General Hospital Healey Center Experience
115
Streamlining ALS Clinic Operations with a Google Sheet-Based Tracking System
116
Measuring Clinician Satisfaction in a Newly Established Multidisciplinary ALS Clinic
117
Multidisciplinary Clinic Attendance and Patterns of Care in the U.S. National ALS Registry, 2013-2023
118
Quality improvement in ALS multidisciplinary clinic: increased patient satisfaction after redesign
119
Navigating Complex Conversations-The Provider's Perspective
120
IMproving PAlliative Care Teamwork in ALS (IMPACT-ALS): Addressing Existential Distress Among ALS Care Partners
121
Longitudinal Progression of Depression in Amyotrophic Lateral Sclerosis Despite Similar Functional Decline: A Retrospective Cohort Study from a Multidisciplinary ALS Clinic
122
Implementing the Distress Thermometer in a multidisciplinary ALS clinic
Anchor 1
Abstract #
Abstract Title
The Gupta Family Endowed Prize for Innovation in ALS Care
Drs. Ayeez and Shelena Lalji & Family Student Scholar Award for Repair and Regenerative Mechanisms in ALS
59
Oral Diadochokinetic Rate: A Quantitative Measure of Amyotrophic Lateral Sclerosis Dysarthria
123
IMproving PAlliative Care Teamwork in ALS (IMPACT-ALS): Chaplain Training for Spiritual AIM
124
IMproving PAlliative Care Teamwork in ALS (IMPACT-ALS) Interprofessional Communication Skills Workshop
125
Cumulative Life Stress: Mapping the Biopsychosocial Landscape of Young Women Living with ALS
126
Racial and Ethnic Disparities in ALS Care and Outcomes: A 10-Year Retrospective Review at a Southern California Tertiary Care Center
127
Diagnostic Delay Profile in Amyotrophic Lateral Sclerosis in Puerto Rico: A Retrospective Cohort Study
128
Evaluation of Reported Geographic Clustering of Amyotrophic Lateral Sclerosis, Virginia, 2000-2024
129
Distinct Patterns of Amyotrophic Lateral Sclerosis Mortality After Moderate-to-severe Traumatic Brain Injury and Repeated Mild and Subclinical Traumatic Brain Injury
130
Global prevalence and economic burden of FUS-ALS: a systematic review
131
ASSESSING THE POTENTIAL ROLE OF CHLOROVIRUSES CONTRIBUTING TO GUAMANIAN ALS
133
Reframing ALS Phenotypes Through Afferent Signaling Mechanisms
134
Anatomically defined motor phenotypes reveal dissociated trajectories of progression, neurofilament profiles, and survival in ALS
135
The Nova ALS Registry: Survival and Prognostic Predictors in a US Cohort with High Hispanic Representation
136
Speech Communication and Anxiety Predict Longitudinal Functional Outcomes in ALS Independent of Rural Residence
137
Factors affecting amyotrophic lateral sclerosis disease progression and survival in United States Veterans
138
Six-month ALSFRS-R plateaus in ALS reflect slower but continuing progression within patients: evidence from ROADS and forced vital capacity
139
Characterizing ALS Disease Progression across MiToS Staging Using Multistate Cox Models
140
GLP-1-receptor agonist treatment is associated with shorter survival in people with amyotrophic lateral sclerosis and comorbid diabetes mellitus
141
Longitudinal Functional Decline, Domain-Level Trajectories, and Self-Report Validity of the PLSFRS and ROADS in Primary Lateral Sclerosis
142
Convening and training a patient and caregiver advisory board for a multisite, five year trial among people with ALS and their caregivers
143
The Multidimensional Impact of Spasticity in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis: Results from an International Survey
144
Volunteer-led Proactive Outreach as a Care Bridge in ALS Treatment Centers of Excellence
145
Unmet Needs in ALS: Voices from the Community and Their Care Partners
146
Understanding and Assessing Financial Burden in ALS: Qualitative Exploration of Patient & Care Partner Experiences to Guide Screening Tool Development
147
Patient and Care Partner Perspectives on Advanced Care Planning in Amyotrophic Lateral Sclerosis
148
Online Crowdfunding in ALS Demonstrates Financial Burden and Unmet Care Needs Across the Disease Trajectory
149
Patient and Caregiver Priorities for a Comparative Effectiveness Research Agenda in ALS
150
From Participation to Partnership: Amplifying the Patient Voice in Motor Neuron Disease Research Through NeuroPRO™
151
Beyond Placebo Aversion: Identifying the Trial Attributes That Drive ALS Patient and Caregiver Willingness to Participate
152
Who Gets Left Behind? Understanding Barriers to Participation and Retention in ALS Research
153
Finding Your People: Building a Village (While)in the ALS Storm
154
Understanding Engagement, Interests, and Leadership Potential Within the NEALS Research Ambassador Program: Results of a National Reassessment Survey
155
Limited Access, Not Limited Interest: Increasing Rural ALS Research Participation Through Coordinated Referrals, Education, and Remote Enrollment
157
Tim Lowrey ALS Panels: Lived experience ALS stories for health-care students and professionals
158
Integrating People Living with ALS into Real-Time Research Dialogue Through a Digital Community Platform
159
Drivers of Lumbar Puncture Willingness in the ALL ALS Consortium
160
Characterizing Health System Costs for Multidisciplinary Care in Amyotrophic Lateral Sclerosis (ALS)
161
Evaluation of the Comprehensive Score for Financial Toxicity (COST) Instrument among People Living with ALS
162
Emergency Care Gaps in Amyotrophic Lateral Sclerosis: Survey of Patient and Caregiver Experiences
163
Evaluating Clinical Comparability and Engagement in On-site vs. Remote Participants: Findings from the ASSESS ALL ALS Study
164
Do Current ALS Clinical Trials Reflect the Real-World Patient Population? A Comparative Analysis of Accessibility, Eligibility, and Disease-Stage Alignment
165
Comparing the Impact of Video Integration to Traditional Amyotrophic Lateral Sclerosis (ALS) Visit Communication on Patient and Caregiver Quality of Life (VITALS trial): Trial Design and Enrollment Updates
166
Study Design and Enrollment Updates for the ALL ALS DIGITIZE Substudy
167
Beyond Trial Discovery: Insights from a Navigation Pilot
168
Building a More Diverse ALS Research Cohort: Expanding Hispanic and Latin American Participation in the Target ALS Global Natural History Study
169
SAVA: Real-World Adoption and Engagement of an AI-Powered ALS Clinical Study Navigator Following Public Launch
170
Accelerating ALS Therapeutics Through a Perpetual Platform Trial: Innovation Across the Data Lifecycle
171
Master Protocol IND Lifecycle Management: The HEALEY ALS Platform Trial Experience
173
Connexin-43 hemichannel blockade with Tonabersat: A biomarker-driven phase 2 randomized trial in amyotrophic lateral sclerosis
174
Targeting mitochondrial dysfunction with the clinical candidate NRG5051: a novel disease-modifying approach for ALS
175
A First-in-Human Dose-Escalation Study of Intrathecal INS1202 Gene Therapy in Adults With Amyotrophic Lateral Sclerosis (ALS)
176
Design and Development of Sigma-1 Receptor Analogs
177
Slowing of Functional Decline with Pridopidine Through Week 48 Versus Propensity-Score-Weighted PRO-ACT Controls
178
PREVAiLS (Pridopidine Phase 3 Study To Evaluate Efficacy And Safety In ALS) a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study In ALS
179
The HEALEY ALS Platform Trial Next Generation Design: Optimized master protocol for Regimen I and beyond
180
Healey ALS MyMatch: Program Overview and Latest Trial Updates
181
Healey ALS MyMatch: Digoxin in ACACIA trial and Rapid Drug Purposing in ALS
182
ALS Therapy Evaluation Framework: Selection of Investigational Products for the HEALEY ALS Platform Trial and Healey ALS MyMatch Program
183
HEALEY ALS Platform Trial: Building Better Trials Through Collaboration
184
Advancement of BIIB147, an Antisense Oligonucleotide Designed to Correct STMN2 Splicing, to a First-in-Human Phase 1/2 Study in ALS
185
Real-World Evidence on Treatment Retention, Safety, and Tolerability of Edaravone in Canadian Patients with Amyotrophic Lateral Sclerosis
186
N-of-1 trial of Antisense Oligonucleotide for CHCHD10 ALS, possible signs of efficacy.
187
Association of Edaravone With Improved Progression-Free Survival in Patients With Amyotrophic Lateral Sclerosis: A Propensity Score-Matched Analysis of the Optum Claims Database
188
Association of Edaravone Treatment With Slower Functional Decline in a Real-World Cohort of Patients With Amyotrophic Lateral Sclerosis With Elevated Neurofilament Light Chain
190
Phase 2a Trial of Intranasal Foralumab - BANYAN, a Healey ALS MyMatch Trial
191
Enhancing Enrollment in ALS Clinical Research: Year 2 of The Acceleration Centers of Enrollment (ACE) Initiative
192
FUNCTION ALS: A randomized, double-blind, placebo-controlled, Phase 1 / 2 trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of ascending doses of TRCN-1023 administered by intrathecal injections to adult people living with ALS
193
Targeting Proteostasis in ALS: Mechanism of Action Insights from Preclinical Studies and Phase 1b Clinical Evidence for NUZ-001
194
Use of nonclinical pharmacokinetic/pharmacodynamic (PK/PD) data and translational modeling to support selection of human dose and dosing regimen for TRCN-1023 in People living with ALS
195
An update from GOALS, a first-in-human phase 1b/2 trial of ALN-SOD, an intrathecally-administered small interfering RNA targeting SOD1, in symptomatic SOD1-ALS
197
Long-term (5 years) evaluation of tofersen in SOD1‑ALS: final results from the integrated analysis of Study 101 Parts A/B, a Phase 1/2 ascending dose trial, and the open-label extension
198
Design and Implementation of Regimen I of the HEALEY ALS Platform Trial: Next Generation - Testing NUZ-001
199
2-Year Overall Survival Results From DAZALS: A Phase 2, Randomized Controlled Trial of Dazucorilant, a Selective Glucocorticoid Receptor Modulator, in Amyotrophic Lateral Sclerosis
200
Accelerating Site Activation in the HEALEY ALS Platform Trial: Operational Efficiencies Grounded in Collaboration
201
SEA-NOBI-ALS Expanded Access Program of Ibudilast (MN-166)
202
Results from QRL-101-04: Evidence of target engagement with a selective Kv7.2/7.3 ion channel opener in ALS patients
203
ANQUR: a Phase 1 MAD and Dose-Range Finding Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of QRL-201, A STMN2 Targeting Splice-Switching ASO for the Treatment of Sporadic and C9orf72 ALS
204
Design of a Planned Phase 3 Confirmatory Trial of AP-101, a Human Antibody Targeting Misfolded SOD1, in Sporadic and SOD1-Associated ALS
205
Safety, Tolerability, and Preliminary Efficacy of Multi-site Direct Current Stimulation Treatments to Reduce Motor Neuron Excitability in ALS.
206
Propensity-Matching Analysis Indicates that RAPA-501 Autologous T Stem Cell Therapy Mediates Promising Clinical Benefits in Advanced-Stage ALS Patients
207
Results from PRO-101, a Phase 1b study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of prosetin in participants with ALS
208
Darwin-ALT001 for ALS: Results from a Randomized Phase 1 Study in China and the Design of a Seamless Adaptive U.S. Phase 1 Study
209
C9orf72-ALS Phenotype, Neurofilament Light, and Survival in the HEALEY ALS Platform Trial: Implications for Gene-Targeting Trials
210
Real-World Clinical Characteristics and Disease Progression of SOD1-ALS in Patients Treated with Tofersen
211
Developing selective and directed gene delivery to upper motor neurons by ultrasound-guided opening of the blood brain barrier
212
AI-Generated Digital Twins and Plasma NfL for Trial Planning and Statistical Efficiency in ALS
213
Functionally-Adjusted Life Years
214
The Feasibility, Acceptability, and Preliminary Effect of Simulation of Research Activities with Standardized Patient Actors to Train Multi-Site Clinical Trial Research Staff: A Pre-Post Study
215
Dual Coordination Center Strategies for Centralized and Efficient Vendor Contracting in the ALL ALS Consortium
216
Optimizing Clinical Monitoring Efficiency Using a Risk-Based Clinical Monitoring Strategy in the HEALEY ALS Platform Trial
217
Centralized Operational Dashboards to Enhance Oversight in the ALL ALS Clinical Study
218
Screening Pathway for Early Eligibility Detection (SPEED): Clinician-Supervised Matching Across Concurrently Enrolling ALS Trials
219
Large Language Models for Speller-Based AAC in ALS: A Novel Approach to Efficient, Intent-Based Communication
220
Real-Time Communication Restoration in ALS with a Fully Implanted Speech Brain-Computer Interface
221
Neuroergonomic Optimization of Stimulus and Decoding Parameters in a P300 Speller BCI for ALS Using Multimodal EEG and fNIRS
222
A Generic Code-modulated BCI Decoder with Short Calibration and Reliable Idle-state Detection for Communication in ALS
223
Comparing Noninvasive Visual BCI Paradigms for Communication in ALS: Efficiency, Ergonomics, and User Preference
224
ALS Global Research Initiative (AGRI): Building a Global Open Science Resource to Accelerate ALS Biomarker Discovery
POSTER SESSION 2: October 29 4:50-6:30 PM ET
Anchor 2

POSTER AWARDS

Basic Science Abstract Award

The Basic Science Abstract Award will be given to an outstanding abstract poster presentation focused on basic science. 

Clinical Investigation Abstract Award

The Clinical Investigation Abstract Award will be given to an exceptional abstract poster presenter focused on clinical investigation. 

UMN Achievement Award

The eigth annual UMN Achievement Award will be given to two abstracts focusing on PLS/UMN research. The UMN Achievement Award is supported by the Spastic Paraplegia Foundation (SPF) to promote UMN research and recognize those who contribute significantly to this field. 

SCIENCE HIGHLIGHTS

Science Symposium Presentation

Up to 2 abstract submissions focusing on sporadic ALS will be selected for 10-minute presentations during the Science Symposium portion of our conference.

Vials_edited.jpg

Lightening Science Talks

Up to 12 abstract submissions will be selected for 3-minute presentations during the conference.

  • LinkedIn
  • Twitter
  • Facebook
bottom of page